Beximco Pharmaceuticals Statistics

Total Valuation

Beximco Pharmaceuticals has a market cap or net worth of GBP 242.38 million. The enterprise value is 292.43 million.

Market Cap	242.38M
Enterprise Value	292.43M

Important Dates

The last earnings date was Monday, November 4, 2024.

Earnings Date	Nov 4, 2024
Ex-Dividend Date	Nov 22, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.05%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	297.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.33, with an EV/FCF ratio of 8.44.

EV / Earnings	7.88
EV / Sales	0.99
EV / EBITDA	4.33
EV / EBIT	5.20
EV / FCF	8.44

Financial Position

The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.09.

Current Ratio	2.43
Quick Ratio	0.57
Debt / Equity	0.09
Debt / EBITDA	0.48
Debt / FCF	0.89
Interest Coverage	7.75

Financial Efficiency

Return on equity (ROE) is 11.66% and return on invested capital (ROIC) is 9.18%.

Return on Equity (ROE)	11.66%
Return on Assets (ROA)	7.61%
Return on Capital (ROIC)	9.18%
Revenue Per Employee	49,129
Profits Per Employee	6,512
Employee Count	1,122
Asset Turnover	0.64
Inventory Turnover	1.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.07% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-17.07%
50-Day Moving Average	27.52
200-Day Moving Average	34.71
Relative Strength Index (RSI)	59.90
Average Volume (20 Days)	85,097

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beximco Pharmaceuticals had revenue of GBP 280.04 million and earned 37.12 million in profits. Earnings per share was 0.08.

Revenue	280.04M
Gross Profit	124.00M
Operating Income	53.19M
Pretax Income	47.77M
Net Income	37.12M
EBITDA	63.23M
EBIT	53.19M
Earnings Per Share (EPS)	0.08

Full Income Statement

Balance Sheet

The company has 8.16 million in cash and 30.75 million in debt, giving a net cash position of -22.59 million.

Cash & Cash Equivalents	8.16M
Total Debt	30.75M
Net Cash	-22.59M
Net Cash Per Share	n/a
Equity (Book Value)	333.92M
Book Value Per Share	0.69
Working Capital	82.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 45.81 million and capital expenditures -11.16 million, giving a free cash flow of 34.65 million.

Operating Cash Flow	45.81M
Capital Expenditures	-11.16M
Free Cash Flow	34.65M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 44.28%, with operating and profit margins of 18.99% and 13.25%.

Gross Margin	44.28%
Operating Margin	18.99%
Pretax Margin	17.06%
Profit Margin	13.25%
EBITDA Margin	22.58%
EBIT Margin	18.99%
FCF Margin	12.38%

Dividends & Yields

Beximco Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-7.55%
Years of Dividend Growth	n/a
Payout Ratio	26.64%
Buyback Yield	0.05%
Shareholder Yield	0.05%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.1.

Last Split Date	Nov 23, 2020
Split Type	Forward
Split Ratio	1.1

Scores

Beximco Pharmaceuticals has an Altman Z-Score of 3.86.

Altman Z-Score	3.86
Piotroski F-Score	n/a